Orca Bio
About Orca Bio
Orca Bio is a late-stage biotechnology company focused on developing high-precision cell therapies for cancer and autoimmune diseases. Its investigational allogeneic T-cell programs leverage regulatory T cells to pursue safer, more effective outcomes. The company emphasizes precise manufacturing and a patient-centric mission to deliver the promise of cell therapy without compromise, with operations and pipeline exploration centered on biomedical advances in life sciences.
Recent News
FDA Delays Decision on Orca Bio Cell Therapy After Filing More Manufacturing Data
FDA Grants RMAT Status to Orca-Q in High-Risk Hematologic Malignancies
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
Orca Adds $250M in Financing to Back Launch of T Cell Therapy
Orca Bio Banks $250M Series F Funding
Recent Deals
No recent deals for this company.